102 related articles for article (PubMed ID: 8301809)
1. Nutritional parameters observed during 28-day infusion of recombinant human tumor necrosis factor-alpha.
Hardin TC; Koeller JM; Kuhn JG; Roodman GD; Von Hoff DD
JPEN J Parenter Enteral Nutr; 1993; 17(6):541-5. PubMed ID: 8301809
[TBL] [Abstract][Full Text] [Related]
2. Cachectic effects of recombinant human tumor necrosis factor in rats.
Darling G; Fraker DL; Jensen JC; Gorschboth CM; Norton JA
Cancer Res; 1990 Jul; 50(13):4008-13. PubMed ID: 2354450
[TBL] [Abstract][Full Text] [Related]
3. Leptin and TNF-alpha levels in patients with chronic obstructive pulmonary disease and their relationship to nutritional parameters.
Calikoglu M; Sahin G; Unlu A; Ozturk C; Tamer L; Ercan B; Kanik A; Atik U
Respiration; 2004; 71(1):45-50. PubMed ID: 14872110
[TBL] [Abstract][Full Text] [Related]
4. Possible biological indicators of the response to recombinant tumour necrosis factor alpha in patients with advanced neoplasms.
Braczkowski R; Zubelewicz B; Romanowski W; Lissoni P; Brivio F
J Exp Clin Cancer Res; 1998 Sep; 17(3):349-54. PubMed ID: 9894774
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy.
Zamkoff KW; Newman NB; Rudolph AR; Young J; Poiesz BJ
J Biol Response Mod; 1989 Oct; 8(5):539-52. PubMed ID: 2795095
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of recombinant human tumor necrosis factor (rHu-TNF:PT-050).
Taguchi T
Cancer Detect Prev; 1988; 12(1-6):561-72. PubMed ID: 3180146
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study.
Spriggs DR; Sherman ML; Michie H; Arthur KA; Imamura K; Wilmore D; Frei E; Kufe DW
J Natl Cancer Inst; 1988 Sep; 80(13):1039-44. PubMed ID: 3411618
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors: a Pediatric Oncology Group study.
Furman WL; Strother D; McClain K; Bell B; Leventhal B; Pratt CB
J Clin Oncol; 1993 Nov; 11(11):2205-10. PubMed ID: 8229135
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy.
Schwartz JE; Scuderi P; Wiggins C; Rudolph A; Hersh EM
Biotherapy; 1989; 1(3):207-14. PubMed ID: 2642024
[TBL] [Abstract][Full Text] [Related]
10. Portal infusion of tumor necrosis factor increases mortality in rats.
Kahky MP; Daniel CO; Cruz AB; Gaskill HV
J Surg Res; 1990 Aug; 49(2):138-45. PubMed ID: 2381203
[TBL] [Abstract][Full Text] [Related]
11. Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly.
Schiller JH; Storer BE; Witt PL; Alberti D; Tombes MB; Arzoomanian R; Proctor RA; McCarthy D; Brown RR; Voss SD
Cancer Res; 1991 Mar; 51(6):1651-8. PubMed ID: 1998956
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of recombinant human tumor necrosis factor alpha in rhesus monkeys after intravenous administration.
Greischel A; Zahn G
J Pharmacol Exp Ther; 1989 Oct; 251(1):358-61. PubMed ID: 2795465
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor increases serum leptin levels in humans.
Zumbach MS; Boehme MW; Wahl P; Stremmel W; Ziegler R; Nawroth PP
J Clin Endocrinol Metab; 1997 Dec; 82(12):4080-2. PubMed ID: 9398717
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism.
Sherman ML; Spriggs DR; Arthur KA; Imamura K; Frei E; Kufe DW
J Clin Oncol; 1988 Feb; 6(2):344-50. PubMed ID: 3339398
[TBL] [Abstract][Full Text] [Related]
15. Intra-arterial administration of TNF-alpha followed by arterial ablation is an effective therapy for a regionally confined TNF-resistant rat mammary adenocarcinoma.
Badgwell BD; Valentino DJ; Jeffes EB; Dieffenbach K; Dulkanchainun SB; Yamamoto RS; Granger GA; Jakowatz JG; Carson WE
Cancer Immunol Immunother; 2003 Jan; 52(1):10-6. PubMed ID: 12536235
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo.
Demetri GD; Spriggs DR; Sherman ML; Arthur KA; Imamura K; Kufe DW
J Clin Oncol; 1989 Oct; 7(10):1545-53. PubMed ID: 2506316
[TBL] [Abstract][Full Text] [Related]
17. Effect of tumor necrosis factor on the human fibrinolytic system.
Silverman P; Goldsmith GH; Spitzer TR; Rehmus EH; Berger NA
J Clin Oncol; 1990 Mar; 8(3):468-75. PubMed ID: 2106575
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients.
Feinberg B; Kurzrock R; Talpaz M; Blick M; Saks S; Gutterman JU
J Clin Oncol; 1988 Aug; 6(8):1328-34. PubMed ID: 3411344
[TBL] [Abstract][Full Text] [Related]
19. Effects of tumor necrosis factor-alpha/cachectin on thyroid hormone metabolism in mice.
Ozawa M; Sato K; Han DC; Kawakami M; Tsushima T; Shizume K
Endocrinology; 1988 Sep; 123(3):1461-7. PubMed ID: 3402392
[TBL] [Abstract][Full Text] [Related]
20. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
